Pfizer and partner BioNTech say initial laboratory studies suggest a third dose of their COVID-19 mRNA vaccine will "neutralize the Omicron variant" and that the two-dose regimen may still induce protection against severe disease.
Pfizer and BioNTech provide an update on the 'Omicron' variant
December 9, 2021 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Nasal adrenaline to be added to the PBS for people at risk of anaphylaxis
June 30, 2026 - - Latest News -
When it comes to negotiating with government, trust actions and not words
June 30, 2026 - - Latest News -
Neuren partner secures critical European backing for Rett syndrome therapy
June 30, 2026 - - Australian Biotech -
Disappointment for CSL as Europe recommends reversing approval of therapy
June 30, 2026 - - BioPharma -
Ipsen therapy approved in Australia for rare genetic disorder
June 30, 2026 - - Latest News -
New MSD vaccine listed on national program with expanded eligibility
June 30, 2026 - - Latest News -
A comment that highlights how complexity is making the challenge more challenging
June 29, 2026 - - Latest News


